AMLN: Summary for Amylin Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Tuesday, February 9, 2010, 10:35am EST - Canadian Markets close in 5 hours and 25 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Amylin Pharmaceuticals, Inc. (AMLN)

At 10:20 EST: 17.56 USD

0.23 (1.33%)

MORE ON AMLN

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Amylin Pharmaceuticals, Inc. (NasdaqNM:AMLN) Delayed quote data

Last Trade:	17.56 USD
Trade Time:	10:20AM EST
Change:	0.23 (1.33%)
Prev Close:	17.33
Open:	17.51
Bid:	17.56 x 700
Ask:	17.57 x 1200
1y Target Est:	19.56

Day's Range:	17.50 - 17.73
52wk Range:	7.89 - 19.99
Volume:	272,345
Avg Vol (3m):	3,218,870
Market Cap:	2.49B
P/E (ttm):	N/A
EPS (ttm):	-1.32
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add AMLN to Portfolio

Download Data

HEADLINES

•	Biotech ETFs Immune To Broad Selling
	Investor's Business Daily (Mon 5:34pm)

•	Alkermes Retains Neutral Rec
	Zacks.com (Mon 3:07pm)

•	AMYLIN PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Fri, Feb 5)

•	Alkermes Testing its Version of Popular Schizophrenia Drug
	at TheStreet.com (Thu, Feb 4)

•	Alkermes Testing Schizophrenia Drug
	at TheStreet.com (Thu, Feb 4)

•	Novo Nordisk Has High Hopes for Diabetes Blockbuster
	at Seeking Alpha (Wed, Feb 3)

•	The Shaky State Of California Biopharma
	at CNBC (Tue, Feb 2)

•	Eli Lilly and the Depression-Diabetes Circle
	at Minyanville.com (Tue, Feb 2)

•	UPDATE - Novo Nordisk ups outlook, Q4 EBIT beats consensus
	at Reuters (Tue, Feb 2)

•	2-Star Stocks Poised to Plunge: MannKind?
	at Motley Fool (Tue, Feb 2)

•	Weekly Street Sentiment: Mostly Cloudy with a Chance of Sunshine
	at Seeking Alpha (Tue, Feb 2)

•	Monday Options Recap
	at Seeking Alpha (Mon, Feb 1)

•	PREVIEW-Novo Nordisk Q4 seen down but 2010 rosier
	at Reuters (Mon, Feb 1)

•	Novo Nordisk Awaits China Approval of Diabetes Treatment
	at Seeking Alpha (Sun, Jan 31)

•	[$$] 13D Filings
	at Barrons.com (Sat, Jan 30)

More Headlines for AMLN...

ANALYST

EPS Est (next year) (Dec-10) :	-0.85
EPS Est (in 2 years) (Dec-11) :	-0.33
Avg Rec (current)*:	2.8
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Amylin Pharmaceuticals, Inc., a biopharmaceutical company, focuses on improving the lives of people with diabetes, obesity, and other diseases through the discovery, development, and commercialization of innovative medicines.

Full Company Profile

Add to Portfolio

Email to a Friend

•